What's Happening?
Ionis Pharmaceuticals has announced the completion of enrollment for the pivotal cohort of its Phase 3 REVEAL study, which is evaluating obudanersen, an investigational RNA-targeted medicine for Angelman syndrome (AS). The study enrolled 136 participants
aged 2 to under 18 years with a confirmed diagnosis of AS. The adult cohort is expected to complete enrollment by the third quarter of 2026. The REVEAL study aims to assess the efficacy of obudanersen in improving expressive communication and other symptoms associated with AS. Topline data from the study is anticipated in the second half of 2027.
Why It's Important?
The completion of enrollment in this study marks a significant step towards potentially providing a disease-modifying treatment for Angelman syndrome, a rare neurodevelopmental disorder with no approved therapies. The study's outcomes could lead to a new treatment option for patients, addressing significant unmet medical needs. The success of this trial could also bolster Ionis Pharmaceuticals' position in the field of RNA-targeted therapies, potentially impacting the company's market performance and future research directions.
What's Next?
Ionis plans to advance obudanersen into the Phase 3 CHAMPION study, targeting patients with different genetic profiles of Angelman syndrome. The CHAMPION study is expected to begin before the end of 2026. The results from these studies could influence regulatory decisions and the potential approval of obudanersen as a treatment for Angelman syndrome.
